• Explore /
  • Poster
  • / Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.

Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.

Abstract Video & Slides Poster

Authors

null

Jacob Stephen Thomas

Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA

Jacob Stephen Thomas , Jennifer Eva Selfridge , Costantine Albany , Matthew H. Taylor , Inderjit Mehmi , Vineet Kwatra , Siwen Hu-Lieskovan , Paul L. de Souza , Judith Dubal Llorin-Sangalang , Kartik Aysola , Omid Hamid

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT05180799

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 2602)

DOI

10.1200/JCO.2024.42.16_suppl.2602

Abstract #

2602

Poster Bd #

81

Abstract Disclosures

Similar Posters

First Author: Geraldine Pignot

First Author: Bernardo Leon Rapoport

First Author: Jacob J. Adashek

First Author: Vanessa Anne Eulo